Spiro-quinolylhydantoins, process for their preparation and pharmaceutical compositions thereof
申请人:PFIZER INC.
公开号:EP0014079B1
公开(公告)日:1981-11-18
US4176185A
申请人:——
公开号:US4176185A
公开(公告)日:1979-11-27
Spiro-quinolylhydantoins
申请人:Pfizer Inc.
公开号:US04176185A1
公开(公告)日:1979-11-27
Novel spiro-quinolylhydantoin derivatives useful as aldose reductase inhibitors and as therapeutic agents for the treatment of chronic diabetic complications are disclosed. Preferred compounds include spiro[imidazolidin-4,4'-pyrano[3,2-h]quinolin]-2,5-dione and spiro[imidazolidin-4,4'-pyrano[2,3-f]quinolin]-2,5-dione.